News · 26 weeks50-17%
2026-03-082026-08-30
Mix2090d
- Insider9(45%)
- Other6(30%)
- SEC Filings4(20%)
- Leadership1(5%)
Latest news
25 items- SECAdicet Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Adicet Bio, Inc. (0001720580) (Filer)
- PRAdicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate UpdatePrula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first candidate expected to enter clinical development in 2H 2027 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of pru
- PRAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026. One individual was hired by Adicet in August 2026 and granted new hire non-qualified stock options to purchase 1,500 shares of Adicet’s common stock with an exercise price of $8.70 per share, the closing price of Adicet’s common stock as reported by Nasdaq on August 31, 2026. One-fourth of the shares underlying the employee’s option will vest on the one-year anniversary of the employee’s start date
- PRAdicet Bio Announces FDA Clearance of IND Application for ADI-212Phase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company plans to initiate Phase 1 enrollment in patients with mCRPC in the fourth quarter of 2026. "ADI-212 marks an important mi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adicet Bio Inc.SCHEDULE 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
- INSIDERSEC Form 4 filed by Chief Medical Officer Klickstein Lloyd4 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECSEC Form 10-Q filed by Adicet Bio Inc.10-Q - Adicet Bio, Inc. (0001720580) (Filer)
- SECAdicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adicet Bio, Inc. (0001720580) (Filer)
- PRAdicet Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesCompany to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 months follow-up, including 13 patients with at least 12 months of follow-up; topline results now anticipated in 3Q/2026 Productive interactions with the U.S. Food and Drug Administration (FDA) informing potential pivotal trial design for LN, supporting planned start up activities in 2H/2026 On track for regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) in 3Q/2026 with enrollment anticipated to begin 4Q/2026, pending re
- PRLipocine Appoints Michael J. Grissinger to Board of DirectorsSALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026. "We are pleased to welcome Mike Grissinger to our Board of Directors," said Dana Ono, Ph.D., Chairman of the Board of Lipocine. "Mike brings extensive experience leading pharmaceutical licensing, corporate development, and mergers and acquisitions. As Lipocine works to advance the pipeline and pursue partnerships for
- PRAdicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth ConferenceAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30 a.m. ETThe live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc.Adicet Bio, Inc.
- INSIDERSEC Form 4 filed by President & CEO Schor Chen4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Aftab Blake4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Dubin Steve4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Chodakewitz Jeffrey4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Grissinger Michael4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Sinclair Andrew4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Peng Katie4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Director Klickstein Lloyd4 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECAdicet Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Adicet Bio, Inc. (0001720580) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Adicet Bio Inc.10-K/A - Adicet Bio, Inc. (0001720580) (Filer)
- PRAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York. Details of the event are as follows: Date: Thursday, June 4, 2026 Time: 7:35a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. i
- SECSEC Form S-8 POS filed by Adicet Bio Inc.S-8 POS - Adicet Bio, Inc. (0001720580) (Filer)
- SECSEC Form 10-Q filed by Adicet Bio Inc.10-Q - Adicet Bio, Inc. (0001720580) (Filer)
- SECAdicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adicet Bio, Inc. (0001720580) (Filer)
ACET FAQ
7 questionsWhat does Adicet Bio Inc. do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which...Where does ACET stock trade?
Adicet Bio Inc. (ACET) is listed on NASDAQ.What sector and industry is ACET in?
Adicet Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adicet Bio Inc. go public?
Adicet Bio Inc. (ACET) completed its IPO in 2018.What are analysts saying about ACET?
Adicet Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1900.00 price target on 2026-05-05. Recent price targets range from $600.00 to $2800.00.What companies are similar to ACET?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ACET side-by-side with any of them on Quantisnow.How can I track ACET on Quantisnow?
Quantisnow aggregates Adicet Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACET to receive live email and push alerts on every new disclosure.